It is, therefore, imperative to better understand the mechanisms that might be involved in resistance to KRAS-targeted therapies in CRC to unveil novel combinatorial therapies that can improve their therapeutic efficacy or identify biomarkers predictive of response. Here, KRAS is linked to colorectal carcinoma.